CG Oncology spotlights oncolytic virus combo data ahead of full readout due next year
CG Oncology has been quietly chugging along — only giving updates at sequential cancer conferences ahead of a full readout on its oncolytic virus cancer therapy next year.
In its latest at SITC, the Irvine, CA-based biotech showed up with longer-term data on its therapy, CG0070, in combination with Merck’s Keytruda. While the data are still early, they suggest more durability where the biotech had initially turned heads on efficacy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.